Savara will hold an investor call to review the key findings from the important Phase 3 IMPALA-2 trial of Molgramostim Nebulizer Solution in patients with aPAP.

XLV Health Care / /

Savara Inc. (Nasdaq: SVRA), a biopharmaceutical company specializing in rare respiratory diseases, stated that it will hold a conference call and webcast the following day.

Savara will hold an investor call to review the key findings from the important Phase 3 IMPALA-2 trial of Molgramostim Nebulizer Solution in patients with aPAP. Read More »